Diabetic Cardiovascular Complications: Multi-Omics Analysis

Last updated: February 7, 2025
Sponsor: Second Xiangya Hospital of Central South University
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Diabetic Vitreous Hemorrhage

Diabetic Kidney Disease

Diabetic Foot Ulcers

Treatment

N/A

Clinical Study ID

NCT06824233
LYF20240324
  • Ages 20-70
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this observational study is to learn about the molecular mechanisms underlying cardiovascular complications in individuals with type 2 diabetes (T2DM) and how they differ from healthy individuals. The study will also identify biomarkers and potential therapeutic targets for better managing diabetes-related heart disease.

The main questions it aims to answer are:

  1. What molecular changes are associated with cardiovascular complications in T2DM patients compared to healthy individuals?

  2. How do genetic, gene expression, and protein profiles differ between T2DM patients with and without cardiovascular complications? Researchers will compare the molecular profiles of three groups: healthy controls, individuals with T2DM but no cardiovascular complications, and those with T2DM and cardiovascular complications.

Participants will:

  1. Provide blood samples for genomics, transcriptomics, and proteomics analysis

  2. Undergo standard clinical tests such as blood pressure, echocardiogram, and ankle-brachial index measurements

  3. Be followed for 12 to 24 months to track the development of cardiovascular events Participate in follow-up phone interviews to record major cardiovascular events like heart attacks or strokes

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age: Patients aged between 20 and 70 years.

  2. Coronary Angiography: Patients who have undergone coronary angiography at the SecondXiangya Hospital of Central South University for various reasons.

  3. Informed Consent: Patients who have signed the informed consent form and are willingto participate in the collection and analysis of multi-omics data.

  4. Medical History and Samples: Patients who can provide complete medical history andbiological samples.

Exclusion

Exclusion Criteria:

  1. Severe Diseases or Malignancy: Patients with other severe diseases or malignanciesthat may affect the study.

  2. Cognitive or Psychiatric Disorders: Patients with cognitive or psychiatric disordersthat would prevent participation or cooperation in the study.

  3. Pregnancy or Lactation: Women who are pregnant or breastfeeding.

  4. Short Life Expectancy: Patients with a life expectancy of less than 6 months.

  5. Inability to Provide Consent: Patients unable or unwilling to provide informedconsent.

Study Design

Total Participants: 300
Study Start date:
March 01, 2025
Estimated Completion Date:
March 01, 2028